Chemotherapy in HER2-Positive Early Breast Cancer: Less is More

Chemotherapy in HER2-Positive Early Breast Cancer: Less is More. Does removing carboplatin from the standard TCHP regimen compromise pathological complete response (pCR) or simply spare patients added toxicity? Explore the NeoCARH-HP trial, which pits full-dose TCHP against THP (carboplatin-free) in Stage II-III disease, and see whether streamlined, less-toxic THP can deliver the same cure rate.

In this concise breakdown you’ll learn:
* How carboplatin contributes to efficacy and side effects
* pCR results head-to-head (TCHP vs THP)
* Key safety signals and real-world implications for de-escalation strategies in HER2-positive early breast cancer

🗂️ CHAPTERS
00:00 Introduction
00:24 Understanding the TCHP Regimen
00:38 Carboplatin: Efficacy and Side Effects
00:44 The NeoCARH-HP Trial: TCHP vs THP Explained
01:09 Comparing Pathological Complete Response (pCR) Rates
01:30 Examining Carboplatin’s Necessity in Treatment
02:00 NeoCARH-HP Trial: Key Findings on Carboplatin Omission
02:34 Side-Effect Comparison: THP vs TCHP
03:02 Implications for Future HER2+ Breast Cancer Protocols
03:37 De-escalation in Oncology: A Modern Approach


#YouTubeHealth #HealthInformation #HER2+ #carboplatin

About DR ESTEVA:
Francisco J. Esteva, MD, PhD is a practicing physician located in New York, NY, specializing in Oncology with a focus on breast cancer. His education includes an Oncology Fellowship at Georgetown University Hospital and Internal Medicine Residency at Cooper Medical School of Rowan University. Prior to his current position as Division Chief at Lenox Hill Hospital, Dr. Esteva has held professorship positions at NYU and The University of Texas MD Anderson Cancer Center, as well as serving as VP Clinical Development for Cellectis. In addition to multiple esteemed publications, he has led more than 100 clinical trials related to breast cancer treatments, diagnostics and prognostic/predictive markers. Dr. Esteva was recognized as a Fellow by the American College of Physicians in 2002, elected as a member of The American Society for Clinical Investigation in 2010 and awarded the 2019 Physician of Impact award by the NYC chapter of the Susan G. Komen Foundation. In 2024, he was elected to the NYC American Cancer Society Board of Advisors.

MEDICAL DISCLAIMER
The content in this video is provided for informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have seen in this video.

NON-SPONSORSHIP & AFFILIATION DISCLAIMER
This video is not sponsored. The mention of any products, medications, or brands (e.g., carboplatin, docetaxel, trastuzumab, pertuzumab) is for educational illustration only and does not constitute an endorsement. Furthermore, any advertisements that may appear on this video are placed by YouTube; I am not affiliated with and do not endorse the advertised products or services.